Table 5 Tumor characteristics associated with six-marker immunohistochemistry-based subtypesa in the AMBER consortium
From: Frequency of breast cancer subtypes among African American women in the AMBER consortium
IHC-based subtype | Number | High combined grade(3 vs. 1/2) | Large tumor size (>2 vs. ≤2 cm) | Positive lymph node status (positive vs. negative) | High stage (III/IV vs. I/II) | ||||
|---|---|---|---|---|---|---|---|---|---|
n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | n (%) | OR (95% CI) | ||
Luminal A | 512 | 78 (16) | 1.00 (ref) | 198 (39) | 1.00 (ref) | 196 (39) | 1.00 (ref) | 69 (14) | 1.00 (ref) |
Luminal B | 333 | 158 (48) | 4.99 (3.61–6.91) | 152 (46) | 1.33 (1.01–1.76) | 130 (40) | 1.03 (0.77–1.37) | 44 (14) | 0.98 (0.66–1.48) |
ER-/HER2+ | 111 | 86 (82) | 24.02 (13.82–41.75) | 57 (51) | 1.67 (1.11–2.53) | 62 (58) | 2.16 (1.41–3.31) | 26 (24) | 2.02 (1.21–3.36) |
Basal-like | 425 | 365 (90) | 46.13 (30.90–68.86) | 252 (59) | 2.31 (1.78–3.00) | 173 (41) | 1.09 (0.84–1.42) | 62 (15) | 1.10 (0.76–1.60) |